Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin

Experimental Animals
Yoshiaki KatsudaTakeshi Ohta

Abstract

The spontaneously diabetic torii (SDT) fatty rat is a new model of type 2 diabetes showing overt obesity, hyperglycemia and hyperlipidemia. With early onset of diabetes mellitus, diabetic microvascular complications, including nephropathy, peripheral neuropathy and retinopathy, are observed at young ages. In the present study, blood glucose levels of female SDT fatty rats were controlled with phlorizin, a non-selective SGLT inhibitor, to examine whether and how these complications are caused by hyperglycemia. Phlorizin treatment adequately controlled plasma glucose levels during the experiment. At 29 weeks of age, urinary albumin excretion considerably increased in SDT fatty rats. Glomerulosclerosis and tubular pathological findings also indicate diabetic nephropathy. These renal parameters tended to decrease with phlorizin; however, effects were partial. Sciatic nerve conduction velocities were significantly delayed in SDT fatty rats compared with Sprague-Dawley (SD) rats. Intraepidermal nerve fiber density, an indicator of subclinical small nerve fiber neuropathy, significantly decreased in SDT fatty rats. Retinal dysfunction (prolongation of peak latency for oscillatory potential in electroretinograms) and histopathological ...Continue Reading

References

Jul 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C GuijarroW F Keane
Aug 3, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C Y HsuG C Curhan
May 7, 2004·Brain : a Journal of Neurology·Chia-Tung ShunSung-Tsang Hsieh
Dec 30, 2004·Diabetes/metabolism Research and Reviews·Joel R L EhrenkranzJesse Roth
Aug 22, 2006·Diabetes, Obesity & Metabolism·T SasaseM Matsushita
Oct 14, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M HorstinkUNKNOWN Movement Disorder Society-European Section
Mar 12, 2008·Diabetes·Valentine BrusseeDouglas W Zochodne
Apr 19, 2008·Experimental Animals·Kenichi MatsuiMutsuyoshi Matsushita
Sep 5, 2008·Experimental Diabetes Research·Slava MalatialiMario Barac-Nieto
Nov 11, 2008·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Muhammad A Abdul-Ghani, Ralph A DeFronzo
Mar 13, 2010·Experimental Animals·Yukihito IshiiMutsuyoshi Matsushita
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Jul 28, 2010·Experimental Animals·Yukihito IshiiTakeshi Ohta
Dec 4, 2010·The Journal of Veterinary Medical Science·Yukihito IshiiTakeshi Ohta
Aug 2, 2012·The Journal of Veterinary Medical Science·Takayuki YamaguchiMutsuyoshi Matsushita
Dec 12, 2012·Oxidative Medicine and Cellular Longevity·Horacio OsorioBruno Escalante
Apr 29, 2014·Experimental Animals·Yoshiaki KatsudaTakahisa Yamada

❮ Previous
Next ❯

Citations

Aug 7, 2019·Pharmacology Research & Perspectives·Paul OranjeGerard J P van Westen
Oct 23, 2019·Journal of Diabetes Research·Yoshiaki TanakaAkihiro Kakehashi
Jun 2, 2018·BioMed Research International·Jéssica P Álvarez-RendónJuan R Riesgo-Escovar
Dec 16, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jie ZhangQingsong Jiang
May 7, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Tsukasa NozuToshikatsu Okumura

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
biopsies

Software Mentioned

Scope
EXSUS
CAC EXICARE
PowerLab

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.